A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells

Abstract Background Human epidermal growth factor receptor 2 (HER2) is overexpressed in multiple cancers, which is associated with poor prognosis. Herceptin and other agents targeting HER2 have potent antitumor efficacy in patients with HER2-positive cancers. However, the development of drug resista...

Full description

Bibliographic Details
Published in:Journal of Experimental & Clinical Cancer Research
Main Authors: Shengnan Yu, Jing Zhang, Yongxiang Yan, Xudong Yao, Lijuan Fang, Hui Xiong, Yang Liu, Qian Chu, Pengfei Zhou, Kongming Wu
Format: Article
Language:English
Published: BMC 2019-08-01
Subjects:
Bispecific antibody
HER2
CD3
Breast cancer
Knobs-into-holes
Online Access:http://link.springer.com/article/10.1186/s13046-019-1354-1

Internet

http://link.springer.com/article/10.1186/s13046-019-1354-1

Similar Items